R EGULATION A+ O FFERING S UMMARY M Y O M O , I N C . O VE R VI E W Myomo, Inc. (“Myomo” or the “Company”) is a commercial stage medical robotics company that offers expanded mobility for those suffering from neurological disorders and upper-limb paralysis. Based on patented technology developed at MIT and by the Company, Myomo develops and markets the MyoPro ® product line of lightweight, powered arm braces to restore function in the paralyzed or weakened arms and hands of individuals that have suffered a stroke, spinal cord or nerve injury, or other neuro-muscular disability. It is sold through clinical relationships with VA hospitals and leading rehabilitation hospitals and Orthotics and Prosthetics (“O&P”) practices. Several hundred have been successfully used by patients. It is the only device that, using a patient’s own neurological signals, can restore their ability to use their arms and hands so that they can return to work, live independently and reduce their cost of care.

G RO W T H S T R A TE G Y Myomo’s go-to-market model includes a direct sales force calling on VA hospitals and O&P practices that provide the device to their patients, as well as marketing outreach to physicians and therapists who refer patients. The MyoPro ® product line is approved by the VA system, and 20 VA facilities have already ordered devices. Myomo’s devices are currently referred for patients at leading rehabilitation facilities, including Mayo Clinic, Cleveland Clinic, Massachusetts General Hospital, Kennedy Krieger Institute and Loma Linda Medical Center, among others. The Company recently entered into a distribution agreement with Ottobock, a worldwide leader in orthotics and prosthetics, which has begun to market the MyoPro® product through its US sales force, and is planning its international expansion. Clinical research recently conducted by The Ohio State University Stroke Center and published in American Journal of Physical Medicine & Rehabilitation shows a clinically significant instantaneous reduction in upper extremity impairment through use of MyoPro®. Additional clinical studies are underway with the Rehabilitation Institute of Chicago and the Mayo Clinic.

COMPANY INFO HQ: Cambridge, MA Founded: 2006 FTE: 22 Industry: Medical Devices Product: MyoPro®

INTELLECTUAL PROPERTY Exclusive license on IP out of MIT in addition to Myomo’s own patents

UNIT SHIPMENTS 600+ since inception

PREVIOUS CAPITAL RAISES Series A, B, C, A-1, B-1 ~$20MM Raised to Date

REG A+ OFFERING Form 1A Qualified by SEC Expected closing in May 2017 Intends to list on NYSE MKT under “MYO”

TRIPOINT GLOBAL EQUITIES [email protected]

I N VE S TM E N T C O N S I D E R A TI O N S - Large upper limb paralysis orthotics market: ~3 million individuals in the US and ~350,000 new cases each year. - Proprietary technology founded on safe, reliable, non-invasive brain-machine interface developed at MIT in collaboration with Harvard Medical School and exclusively licensed to Myomo. - Platform technology reducing total cost of care and with growing body of clinical evidence. - Commercial stage: established distribution channels, geographic and product line expansion plans, clear reimbursement roadmap, 70%+ gross margins. - Experienced leadership team of technology executives and healthcare professionals.

F OR

A D D I T I ONA L I N F O R M A T I ON , VI S I T W W W . BA N Q . C O / L I S T I N G S / M Y OM O

Myomo Inc.’s offering statement for its initial public offering under Regulation A has been qualified by the Securities and Exchange Commission. The securities offered by Myomo Inc. are highly speculative. Investing in shares of Myomo Inc. involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue. To obtain a copy of the Offering Circular, go to https://www.sec.gov/cgi-bin/browse-edgar?company=myomo+inc&owner=exclude&action=getcompany . This document contains forward-looking statements and management may make additional forward-looking statements. Such written and oral disclosures are made pursuant to the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995. Although we believe our expectations expressed in such forward looking statements are reasonable, we cannot assure you that they will be realized. Investors are cautioned that such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the anticipated results, and therefore we refer you to a more detailed discussion of the risks and uncertainties in the Company’s filings with the Securities & Exchange Commission when available. The forward-looking statements contained in this presentation are made only as of today, and Myomo, Inc. is under no obligation to revise or update these forward-looking statements.